Life Science Investing Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Life Science Investing Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Life Science Investing Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
